Introduction
The combination of trimethoprim and sulphamethoxazole (Septra®, Bactrim@) appears to be an effective and reasonably safe treatment for immunosuppressed patients with documented or suspected Pneumocystis carinii pneumonia (Lau and Young, 1976) . It is also effective as a prophylactic regimen for special patient populations at high risk of developing P. carinii pneumonia (Hughes et al., 1977) and has decided advantage over earlier, more toxic drugs such as pentamidine isethionate (Western, Perera and Schultz, 1970) . The recommended dosage schedule is trimethoprim 20 mg and sulphamethoxazole 100mg/kg body weight/day administered by mouth in 4 equally divided doses for 14 days. These doses produce mean serum concentrations of approximately 4-10 mg/l trimethoprim and 80-120 mg/l sulphamethoxazole (Hughes, Feldman and Sanyal, 1975 confirmed failures of 8 TMP/SMX-treated patients occurred when the treatment period was less than 10 days and the serum drug levels one hr after dosing were low (i.e. TMP 1-5 mg/l and SMX 20-21 mg/l) (Lau and Young, 1976 (Bratton et al., 1939) .
Results
It is evident from Fig. 1 that the TMP and SMX serum concentrations produced by the oral regimen were certainly adequate in spite of frequent emesis. Drug plasma levels obtained from the suppositories were extremely low. Since these drug plasma levels described a dosing interval which can be assumed to approximate steady-state conditions, the relative bioavailability of the drugs from the suppository can be calculated using the equation:
AUC suppository Frel= AUC tablet where Frei is the relative fraction of the dose absorbed using the tablet as the standard for comparison and AUC is the area under the plasma concentration-time curve at steady-stage using the trapezoidal rule (Gibaldi and Perrier, 1975 (Grose, Bodey and Loo, 1979 
